PALISADE BIO, INC. - Common Stock, par value $0.01 per share (PALI)

CUSIP: 696389402

Q3 2024 13F Holders as of 30 Sep 2024

Type / Class
Equity / Common Stock, par value $0.01 per share
Shares outstanding
159,058,879
Total 13F shares
62,098
Share change
+32,020
Total reported value
$220,448
Price per share
$3.55
Number of holders
8
Value change
+$113,672
Number of buys
4
Number of sells
1

Quarterly Holders Quick Answers

What is CUSIP 696389402?
CUSIP 696389402 identifies PALI - PALISADE BIO, INC. - Common Stock, par value $0.01 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of PALI - PALISADE BIO, INC. - Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Yuma Regional Medical Center
3/4/5
10%+ Owner
class O/S missing
1,814,375
$925,331 19 Aug 2021
Marex Group plc
13F
Company
0.02%
35,759
$162,346 30 Jun 2024
13F
ARMISTICE CAPITAL, LLC
13F
Company
0.02%
27,858
$125,361 30 Jun 2024
13F
Thomas Hallam
3/4/5
Chief Executive Officer, Director
mixed-class rows
137,592
mixed-class rows
$29,372 16 Aug 2022
Michael John Dawson
3/4/5
Chief Medical Officer
class O/S missing
15,000
$7,650 29 Mar 2022
Cristina Csimma
3/4/5
Director
mixed-class rows
19,742
mixed-class rows
$5,609 08 Feb 2024
Stephanie Diaz
3/4/5
Director
mixed-class rows
19,680
mixed-class rows
$5,582 08 Feb 2024
UBS Group AG
13F
Company
0%
1,216
$5,473 30 Jun 2024
13F
James R. Neal
3/4/5
Director
mixed-class rows
17,800
mixed-class rows
$4,762 09 Feb 2024
Robert J. Trenschel
3/4/5
Director
mixed-class rows
17,800
mixed-class rows
$4,762 08 Feb 2024
Tower Research Capital LLC (TRC)
13F
Company
0%
738
$3,321 30 Jun 2024
13F
Mary Ann Gray
3/4/5
Director
mixed-class rows
12,700
mixed-class rows
$2,968 21 Nov 2023
Robert Curtis McRae
3/4/5
Chief Operating Officer
mixed-class rows
2,588
mixed-class rows
$1,320 03 Apr 2023
MORGAN STANLEY
13F
Company
0%
140
$630 30 Jun 2024
13F
Federation Des Caisses Desjardins du Quebec
13F
Individual
0%
100
$450 30 Jun 2024
13F
WELLS FARGO & COMPANY/MN
13F
Company
0%
21
$95 30 Jun 2024
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
5
$22 30 Jun 2024
13F
Margery B. Fischbein
3/4/5
Director
class O/S missing
2,100
11 Jul 2024

Institutional Holders of PALISADE BIO, INC. - Common Stock, par value $0.01 per share (PALI) as of Q3 2024

As of 30 Sep 2024, PALISADE BIO, INC. - Common Stock, par value $0.01 per share (PALI) was held by 8 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 62,098 shares. The largest 9 holders included ARMISTICE CAPITAL, LLC, Marex Group plc, JPMORGAN CHASE & CO, Tower Research Capital LLC (TRC), MORGAN STANLEY, Federation des caisses Desjardins du Quebec, UBS Group AG, WELLS FARGO & COMPANY/MN, and BANK OF AMERICA CORP /DE/. This page lists 9 institutional shareholders reporting positions in this security for the Q3 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q3 2024 vs Q2 2024 Across Filers

Q2 2024 holders
7
Q3 2024 holders
8
Holder diff
1
Investor Q2 2024 Shares Q3 2024 Shares Share Diff Share Chg % Q2 2024 Value $ Q3 2024 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .